Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/13/2022 | Buy → Neutral | Guggenheim | |
| 2/25/2022 | $14.00 → $5.00 | Market Perform | SVB Leerink |
| 11/9/2021 | $20.00 → $14.00 | Market Perform | SVB Leerink |
| 10/19/2021 | $25.00 → $22.00 | Equal-Weight | Morgan Stanley |
15-12G - Rubius Therapeutics, Inc. (0001709401) (Filer)
8-K - Rubius Therapeutics, Inc. (0001709401) (Filer)
25 - Rubius Therapeutics, Inc. (0001709401) (Filer)
Dannielle Appelhans to Become President and Chief Executive Officer Pablo J. Cagnoni, M.D., Appointed Chair of the Board of Directors CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that it has initiated a process to explore a range of strategic alternatives to maximize shareholder value and plans to engage an investment bank to act as a strategic advisor for this process. Strategic alternatives that will be evaluated include the sale of all or part of
Dr. Kӧhrer has more than 25 years of RNA research and development experience, including pioneering novel RNA-based technologies into new drug candidates and deciphering transfer RNA (tRNA) biology CAMBRIDGE, Mass., Oct. 17, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Caroline Kӧhrer, Ph.D., as Vice President, Discovery Platform. www.alltrna.com. (PRNewsfoto/Alltrna)" alt="Alltrna unlocks tRNA biology to correct disease. The company's platform incorpo
Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the completion of a $121 million Series C financing, bringing its total funding raised to date to $274 million. In addition to participation by Flagship Pioneering and other Series B investors, four new investors participated, including Kyowa Kirin Co. Ltd. and Hanwha Impact Partners. The proceeds of the financing will be used to grow Cellarity's talent base, strengthen its platform, and advance its pipeline toward the clinic. "We welcome our new investors and appreciate the continued support of our current investors," said Fabrice Chouraqui, PharmD, CEO of Cellarit
Dannielle Appelhans to Become President and Chief Executive Officer Pablo J. Cagnoni, M.D., Appointed Chair of the Board of Directors CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that it has initiated a process to explore a range of strategic alternatives to maximize shareholder value and plans to engage an investment bank to act as a strategic advisor for this process. Strategic alternatives that will be evaluated include the sale of all or part of
Dr. Kӧhrer has more than 25 years of RNA research and development experience, including pioneering novel RNA-based technologies into new drug candidates and deciphering transfer RNA (tRNA) biology CAMBRIDGE, Mass., Oct. 17, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Caroline Kӧhrer, Ph.D., as Vice President, Discovery Platform. www.alltrna.com. (PRNewsfoto/Alltrna)" alt="Alltrna unlocks tRNA biology to correct disease. The company's platform incorpo
BOSTON, July 19, 2022 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases, today announced the appointment of Jose "Pepe" Carmona to its Board of Directors. Mr. Carmona brings over 20 years of leadership experience in the biopharmaceutical industry across a range of roles and therapeutic areas. "We are thrilled to welcome Pepe to our Board of Directors," said Jonathan Montagu, Co-Founder and Chief Executive Officer of HotSpot Thera
On Monday, 36 companies set new 52-week lows. Noteworthy Mentions In Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low was Sirius XM Holdings (NASDAQ:SIRI). The smallest company by market cap to set a new 52-week low was Altamira Therapeutics (NASDAQ:CYTO). China Pharma Holding (AMEX:CPHI) saw the most significant move of the companies, as shares traded down 871.52% to reach its new 52-week low. VEON (NASDAQ:VEON) shares rebounded the highest, with shares trading up 0.0%, bouncing back after reaching its new 52-week low. Stocks dropping to new 52-week lows on Monday: Sirius XM Holdings (NASDAQ:SIRI) shares fell to $4.20 on Monday, setting a new 5
Gainers Unicycive Therapeutics, Inc. (NASDAQ:UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch Renazorb. BridgeBio Pharma, Inc. (NASDAQ:BBIO) shares jumped 59.5% to $17.34 after the company announced positive data for its phase 2 study of Infigratinib in Achondroplasia. Avalon GloboCare Corp. (NASDAQ:ALBT) shares gained 53.5% to $3.3330. Azul S.A. (NYSE:AZUL) gained 45.3% to $6.05 after the company announced a deal to reduce the immediate cash it must expend for leased property. Kala Pharmaceuticals, Inc. (NASDAQ:KALA) rose 28.3% to $21.49. HC Wainwright & Co. maintained Kala Pharmac
Gainers Unicycive Therapeutics (NASDAQ:UNCY) stock moved upwards by 151.2% to $1.23 during Monday's regular session. Trading volume for this security as of 12:30 EST is 77.1 million, which is 22303.6% of its average full-day volume over the last 100 days. The company's market cap stands at $18.5 million. Bellerophon Therapeutics (NASDAQ:BLPH) stock increased by 82.49% to $3.3. Bellerophon Therapeutics's stock is trading at a volume of 11.1 million shares as of 12:30 EST. This is 1023.2% of its average full-day volume over the last 100 days. The company's market cap stands at $31.4 million. BridgeBio Pharma (NASDAQ:BBIO) stock rose 58.0% to $17.18. Trading volume for BridgeBio Pharma's sto
CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report second quarter financial results on Tuesday, August 9, 2022, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. About Rubius Therapeutics Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeuti
CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report first quarter financial results on Tuesday, May 10, 2022, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. About Rubius TherapeuticsRubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™.
Best Responses Include Partial Responses in Certain Patients with Non-Small Cell Lung Cancer, Metastatic Anal Cancer and Metastatic Uveal Melanoma with No Treatment-Related Grade 3/4 Adverse Events or Dose-Limiting Toxicities as of the Cutoff Date Expanding Ongoing Phase 1 Arm of RTX-240 + Pembrolizumab to Focus on Non-Small Cell Lung Cancer and Renal Cell Carcinoma Management to Host Conference Call Today at 1:15 p.m. EDT to Discuss Clinical Data and Clinical Development Next Steps for RTX-240 CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create
SC 13G/A - Rubius Therapeutics, Inc. (0001709401) (Subject)
SC 13G/A - Rubius Therapeutics, Inc. (0001709401) (Subject)
SC 13G/A - Rubius Therapeutics, Inc. (0001709401) (Subject)
Guggenheim downgraded Rubius Therapeutics from Buy to Neutral
SVB Leerink reiterated coverage of Rubius Therapeutics with a rating of Market Perform and set a new price target of $5.00 from $14.00 previously
SVB Leerink reiterated coverage of Rubius Therapeutics with a rating of Market Perform and set a new price target of $14.00 from $20.00 previously
4 - Rubius Therapeutics, Inc. (0001709401) (Issuer)
4 - Rubius Therapeutics, Inc. (0001709401) (Issuer)
4 - Rubius Therapeutics, Inc. (0001709401) (Issuer)